c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty.
Seeliger, M.A., Nagar, B., Frank, F., Cao, X., Henderson, M.N., Kuriyan, J.(2007) Structure 15: 299-311
- PubMed: 17355866 
- DOI: 10.1016/j.str.2007.01.015
- Primary Citation of Related Structures:  
2OIQ - PubMed Abstract: 
The cancer drug imatinib inhibits the tyrosine kinases c-Abl, c-Kit, and the PDGF receptor. Imatinib is less effective against c-Src, which is difficult to understand because residues interacting with imatinib in crystal structures of Abl and c-Kit are conserved in c-Src ...